Navigation Links
MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/30/2008

MOUNTAIN VIEW, Calif., Jan. 30 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008, at 1:40 pm (ET) in New York City.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from diseases that the company believes are not treated adequately by currently available medicines. The company uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The company has several product candidates in clinical development that address large market opportunities, including its two most advanced product candidates: UDB, a proprietary version of nebulized budesonide for the potential treatment of children with asthma; and MAP0004, a proprietary version of orally inhaled dihydroergotamine delivered by MAP Pharmaceuticals' Tempo(TM) inhaler for the potential treatment of migraine. The company is also developing a proprietary combination of an inhaled corticosteroid with a long-acting beta2-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceutical
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
... and burying people who have died of HIV/AIDS in the ... living with the virus. ,"It is indeed shocking to ... dead body of a person who has died of HIV/AIDS ... the Mizoram People Living with HIV/AIDS Society, told IANS. ...
... by a whopping 25 percent annually to fetch India ... Minister Ambika Soni said Wednesday.// ,"The sector has ... foreign patients, we estimate that the country may fetch ... the "Incredible India: The Global Healthcare Destination" brochure. ...
... attack, New York City's Health Department yesterday issued long-awaited ... It comprises medical advice that is supposed to be ... scattered across the United States. ,The guidelines ... illness resulting from 9/11 experiences was previously given by ...
... cases in Africa as of last year hover around ... Nations //.The World Health Organization has suggested an intelligent ... ,The WHO has advised that the ... Africa could be used to give an impetus to ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... pill according to European researchers. The latest study supports ... allergen tablet.// Hay fever and other allergies have long ... result of the immune system reacting to a normally ... is supposed to enhance tolerance of the immune system ...
Cached Medicine News:Health News:Strange Burial Practice Followed for People Affected by HIV/AIDS 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 3Health News:Medical Guidelines to treat 9/11-related illness 2
(Date:5/21/2013)... , May 21, 2013 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... to review the Company,s recent financial results and business ... Surgical will present at the 38 th Annual ... at the Westin Waterfront Hotel on Wednesday, ...
(Date:5/20/2013)... 2013  Volcano Corporation (NASDAQ: VOLC ) ... tools designed to enhance the diagnosis and treatment of ... highlight its efforts to expand research and innovation surrounding ... and iFR ® (Instant Wave-Free Ratio™) 1 ... at EuroPCR 2013 in Paris . ...
(Date:5/20/2013)... May 20, 2013 The Board of ... companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, ... Board.  Guy Mayer , an ... of the Board of Directors and David Johnson, an ... director. Before joining OSI as Board ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 3
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
... 6, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Financial Officer, August J. Moretti will present during the MDB ... Tuesday, May 10, 2011 at 10:00 a.m. Eastern Time.  The ... To access the presentation via the Web, please go ...
Cached Medicine Technology:The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
... is a quick and effective means to seal ... tubes. The compliant inner layer is designed to ... minimizes the risk of aerosol formation and cross-contamination ... use with fewer than 96 wells, and a ...
OptiTape individual sheets. Optically clear sealing tape for OmniUltra PCR plates. 100 pk....
OptiTape - Optically Clear sealing tape for OmniUltra PCR plates plus universal dispenser. 250 sheets....
Medicine Products: